Skip to main content
SpringerLink
Log in

Prokinetic Agents for Gastroparesis

  • Chapter
  • First Online:
Gastroparesis

Part of the book series: Clinical Gastroenterology ((CG))

Abstract

Prokinetic agents are used frequently in patients with gastroparesis. These agents are attractive in treating gastroparesis, as they target the underlying pathophysiology that defines this disorder. Symptom response to treatment with prokinetic agents may not parallel changes in gastric emptying. Only a few prokinetic agents are currently available, since several have been withdrawn. Newer agents, including ghrelin, motilin, and 5-HT4 receptor agonists, are being investigated, which, in preliminary studies, demonstrate efficacy and few side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:1592–622.

    PubMed  Google Scholar 

  2. Camilleri M, Bharucha AE, Farrugia G. Epidemiology, mechanisms, and nanagement of diabetic gastroparesis. Clin Gastroenterol Hepatol. 2011;9:5–12.

    PubMed  Google Scholar 

  3. AMS Gastroparesis Task Force, Abell TL, Bernstein RK, Cutts T, Farrugia G, Forster J, et al. Treatment of gastroparesis: a multidisciplinary review. Neurogastroenterol Motil. 2006;18(4):263–83.

    PubMed  CAS  Google Scholar 

  4. Reddymasu SC, McCallum RW. Pharmacotherapy of gastroparesis. Expert Opin Pharmacother. 2009;10:469–84.

    PubMed  CAS  Google Scholar 

  5. Camilleri M. Clinical practice. Diabetic gastroparesis. N Engl J Med. 2007;356(8):820–9.

    PubMed  CAS  Google Scholar 

  6. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders. Curr Opin Pharmacol. 2008;8:690–6.

    PubMed  CAS  Google Scholar 

  7. Masaoka T, Tack J. Gastroparesis: current concept and management. Gut Liver. 2009;3:166–73.

    PubMed  Google Scholar 

  8. Kashyap P, Farrugia G. Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years. Gut. 2010;59:1716–26.

    PubMed  CAS  Google Scholar 

  9. Vella A, Lee JS, Camilleri M, et al. Effects of pramintide, an amylin analogue, on gastric emptying in type 1 and 2 diaebtes mellitus. Neurogastroenterol Motil. 2002;14:123–31.

    PubMed  CAS  Google Scholar 

  10. Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151:123–9.

    PubMed  CAS  Google Scholar 

  11. van BH, Dubois EA, Pijl H, Cohen AF. New drugs; exenatide and sitagliptin. Ned Tijdschr Geneeskd. 2008;152:876–9.

    Google Scholar 

  12. Veldhuyzen van Zanten SJ, Cleary C, Talley NJ, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol. 1996;91:660.

    PubMed  CAS  Google Scholar 

  13. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, et al. Efficacy of cisapride and domperidone in functional dyspepsia: a meta-analysis. Am J Gastroenterol. 2001;96:689.

    PubMed  CAS  Google Scholar 

  14. Dobrilla G, Comberlato M, Steele A, et al. Drug treatment of functional dyspepsia: a meta-analysis of randomized controlled clinical trials. J Clin Gastroenterol. 1989;11:169.

    PubMed  CAS  Google Scholar 

  15. Sturm A, Holtmann G, Goebell H, Gerken G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion. 1999;60:422–7.

    PubMed  CAS  Google Scholar 

  16. Finney JS, Kinnersley N, Hughes M, et al. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol. 1998;26:312.

    PubMed  CAS  Google Scholar 

  17. Parkman HP, Gonlachanvit S, Hsu C-W, Kantor S, Knight LC, Boden GH, et al. Effect of altering gastric emptying on postprandial glucose following a physiologic meal in type II diabetic patients. Dig Dis Sci. 2003;48:488–97.

    PubMed  Google Scholar 

  18. Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacoloty and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102:2036–45.

    PubMed  CAS  Google Scholar 

  19. Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol. 1999;94(5):1230–4.

    PubMed  CAS  Google Scholar 

  20. Longstreth GF, Malagelada JR, Kelly KA. Metoclopramide stimulation of gastric motility and emptying in diabetic gastroparesis. Ann Intern Med. 1977;86:195.

    PubMed  CAS  Google Scholar 

  21. Snape WJ, Battle WM, Schwartz SS, et al. Metoclopramide to treat gastroparesis due to diabetes mellitus. Ann Intern Med. 1982;96:444.

    PubMed  Google Scholar 

  22. McCallum RW, Ricci DA, Rakatansky H, Behar J, Rhodes JB, Salen G, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care. 1983;6(5):463–7.

    PubMed  CAS  Google Scholar 

  23. Perkel MS, Moore C, Hersh T, et al. Metoclopramide therapy in patients with delayed gastric emptying. Dig Dis Sci. 1979;24:662.

    PubMed  CAS  Google Scholar 

  24. Ricci D, Saltzman M, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastro. 1985;7:25–32.

    CAS  Google Scholar 

  25. Chen JDZ, Pan J, McCallum RW. Clinical significance of gastric myoelectrical dysrhythmias. Dig Dis. 1995;13:275–90.

    PubMed  Google Scholar 

  26. Schade RR, Dugas MC, Lhotsky DM, et al. Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dig Dis Sci. 1985;30:10.

    PubMed  CAS  Google Scholar 

  27. Ganzini L, Casey DE, Hoffman WF, et al. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med. 1993;153:1469.

    PubMed  CAS  Google Scholar 

  28. Shaffer D, Butterfield M, Pamer C, Mackey AC. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J Am Pharm Assoc. 2004;44:661–5.

    Google Scholar 

  29. Rao AS, Camilleri M. Metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31:11–9.

    PubMed  CAS  Google Scholar 

  30. Fass R, Pieniaszek HJ, Thompson JR. Pharmacokinetic comparison of orally-disintegrating metoclopramide with conventional metoclopramide tablet formulation in healthy volunteers. Aliment Pharmacol Ther. 2009;30(3):301–6.

    PubMed  CAS  Google Scholar 

  31. McCallum RW, Valenzuela G, Polepalle S. Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. J Pharm Exp Ther. 1991;258:136–42.

    CAS  Google Scholar 

  32. Trapnell BC, Mavko LE, Birskovich LM, et al. Metoclopramide suppositories in the treatment of diabetic gastroparesis. Arch Intern Med. 1986;146:2278.

    PubMed  CAS  Google Scholar 

  33. Horowitz M, Harding PE, Chatterton BE, et al. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci. 1985;30:1.

    PubMed  CAS  Google Scholar 

  34. Davis RH, Clench MH, Mathias JR. Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms. Dig Dis Sci. 1988;33:1505.

    PubMed  CAS  Google Scholar 

  35. Koch KL, Stern RM, Stewart WR, Vasey MW. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment. Am J Gastroenterol. 1989;84:1069–75.

    PubMed  CAS  Google Scholar 

  36. Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EMM, McCallum RW, et al. Domperidone in the management of symptoms of diabetic gastroparesis; efficacy, tolerability, and quality-of-life outcomes in a multicenter controlled trial. Clin Ther. 1998;20(3):438–53.

    PubMed  CAS  Google Scholar 

  37. Soykan I, Lin Z, Jones S, Chen J, McCallum RW. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson’s disease. Mov Disord. 1997;12(6):952–7.

    PubMed  CAS  Google Scholar 

  38. Sawant P, Das HS, Desai N, Kalokhe S, Patil S. Comparative evaluation of the efficacy and tolerability of itopride hydrochloride and domperidone in patients with non-ulcer dyspepsia. J Assoc Phys India. 2004;52:626–8.

    Google Scholar 

  39. Basque J-R, Noritake M, Mizogami H, Katsura Y. Efficacy of itopride hydrochloride on gastric emptying in patients with diabetic gastroparesis. Gastroenterology. 2005;128(4):A156. abstract.

    Google Scholar 

  40. Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med. 2006;354(8):832–40.

    PubMed  CAS  Google Scholar 

  41. Talley NJ, Tack J, Ptak T, Gupta R, Giguère M. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut. 2008;57(6):740–6.

    PubMed  CAS  Google Scholar 

  42. Farrugia G, Macielaq M, Peeters TL, Sarr MG, Galdes A, Szurszewski JH. Motilin and OHM-11526 activate a calcium current in human and canine jejunal circular smooth muscle. Am J Physiol. 1997;36:G404–12.

    Google Scholar 

  43. Weber FH, Richard RE, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol. 1993;88:485–90.

    PubMed  CAS  Google Scholar 

  44. Moshiree B, Gupta V, Verne GN, Toskes PP. Azithromycin: a new therapy for gastroparesis. Gastroenterology. 2005;128(4):A547. abstract.

    Google Scholar 

  45. Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology. 1993;105:1886.

    PubMed  CAS  Google Scholar 

  46. Parkman HP, Pagano AP, Vozzelli M, Ryan JP. The gastrokinetic effects of erythromycin: myogenic and neurogenic mechanisms of action in the rabbit stomach. Am J Physiol. 1995;269:G418–26.

    PubMed  CAS  Google Scholar 

  47. Parkman HP, Pagano AP, Ryan JP. Erythromycin inhibits pyloric muscle by releasing nitric oxide and VIP through neuronal motilin receptors. Gastroenterology. 1996;111:682–90.

    PubMed  CAS  Google Scholar 

  48. Coulie B, Tack J, Peeters T, Janssens J. Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut. 1998;43:395–400.

    PubMed  CAS  Google Scholar 

  49. Ramirez B, Eaker EY, Drane WE, et al. Erythromycin enhances gastric emptying in patients with gastroparesis after vagotomy and antrectomy. Dig Dis Sci. 1994;39:2295.

    PubMed  CAS  Google Scholar 

  50. Camilleri M. The current role of erythromycin in the clinical management of gastric emptying disorders. Am J Gastroenterol. 1993;88:169.

    PubMed  CAS  Google Scholar 

  51. Janssens J, Peeters TL, Vantrappen G, et al. Erythromycin improves delayed gastric emptying in diabetic gastroparesis. N Engl J Med. 1990;322:1028.

    PubMed  CAS  Google Scholar 

  52. Arts J, Caenepeel P, Verbeke K, Tack J. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut. 2005;54:455–60.

    PubMed  CAS  Google Scholar 

  53. Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol. 2003;98:259–63.

    PubMed  CAS  Google Scholar 

  54. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol. 1993;88:203–7.

    PubMed  CAS  Google Scholar 

  55. Dhir R, Richter JE. Erythromycin in the short- and long-term control of dyspepsia symptoms in patients with gastroparesis. J Clin Gastroenterol. 2004;38(3):237–42.

    PubMed  CAS  Google Scholar 

  56. Petiakis IE, Vrachassotakis N, Sciacca V, et al. Hyperglycemia attenuates erythromycin-induced acceleration of solid phase gastric emptying in idiopathic and diabetic gastroparesis. Scand J Gastroenterol. 1999;34:396.

    Google Scholar 

  57. Ehrenpreis ED, Zaitman D, Nellans H. Which form of erythromycin should be used to treat gastroparesis? A pharmacologic analysis. Aliment Pharmacol Ther. 1998;12:373.

    PubMed  CAS  Google Scholar 

  58. DiBaise JK, Quigley EM. Efficacy of prolonged administration of intravenous erythromycin in an ambulatory setting as treatment of severe gastroparesis. J Clin Gastroenterol. 1999;28:131.

    PubMed  CAS  Google Scholar 

  59. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med. 2004;351:1089–96.

    PubMed  CAS  Google Scholar 

  60. Talley NJ, Verlinden M, Snape W, Beker JA, Ducrotte P, Dettmer A, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying. A randomized double-blind placebo controlled trial. Aliment Pharm Ther. 2000;14:1653–6.

    CAS  Google Scholar 

  61. Talley NJ, Verlinden M, Geenen DJ, Hogan RB, Riff D, McCallum RW, et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomized, double-blind, placebo controlled trial. Gut. 2001;49:395–401.

    PubMed  CAS  Google Scholar 

  62. McCallum RW, US Investigative Team. Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial. Aliment Pharmacol Ther. 2007;26(1):107–16.

    PubMed  CAS  Google Scholar 

  63. McCallum RW, Investigative Team. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis – a randomized, multicentre, placebo-controlled study. Aliment Pharmacol Ther. 2007;26(8):1121–30.

    PubMed  CAS  Google Scholar 

  64. Moshiree B, McDonald R, Hou W, Toskes PP. Comparison of the effect of azithromycin versus erythromycin on antroduodenal pressure profiles of patients with chronic functional gastrointestinal pain and gastroparesis. Dig Dis Sci. 2010;55(3):675–83.

    PubMed  CAS  Google Scholar 

  65. Larson JM, Tavakkoli A, Drane WE, Toskes PP, Moshiree B. Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis. J Neurogastro Motil. 2010;16:407–13.

    Google Scholar 

  66. Sanger GJ, Westaway SM, Barnes AA, et al. GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol Motil. 2009;21:657–64.

    PubMed  CAS  Google Scholar 

  67. Manabe N, Wong BS, Camilleri M. New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs. 2010;19:763–75.

    Google Scholar 

  68. Fraser RJ, Horowitz M, Maddox AF, Dent J. Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis – effects of cisapride. Gut. 1994;35:172–8.

    PubMed  CAS  Google Scholar 

  69. Braden B, Enghofer M, Schaub M, Usadel KH, Caspary WJ, Lembcke B. Long-term cisapride treatment improves diabetic gastroparesis but not glycaemic control. Aliment Pharmacol Ther. 2002;16:1341–6.

    PubMed  CAS  Google Scholar 

  70. Abell TL, Camilleri M, DiMagno EP, Hench VS, Zinsmeister AR, Malagelada JR. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci. 1991;36:616–20.

    PubMed  CAS  Google Scholar 

  71. Rabine JC, Barnett JL. Management of the patient with gastroparesis. J Clin Gastroenterol. 2001;32:11.

    PubMed  CAS  Google Scholar 

  72. Jones MP. Access options for withdrawn motility-modifying agents. Am J Gastroenterol. 2002;97:2184–8.

    PubMed  Google Scholar 

  73. Degen L, Matzinger D, Merz M, Appel-Dingemanse S, Osborne S, Luchinger S, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther. 2001;15:1745–51.

    PubMed  CAS  Google Scholar 

  74. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology. 2000;118:463–8.

    PubMed  CAS  Google Scholar 

  75. Tougas G, Chen Y, Luo D, Salter J, D’Elia T, Earnest DL. Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms. Gastroenterology. 2003;124:A54. abstract.

    Google Scholar 

  76. Kanaizumi T, Nakano H, Matsui Y, Ishikawa H, Shimizu R, Park S, et al. Prokinetic effect of AS-4370 on gastric emptying in healthy adults. Eur J Clin Pharmacol. 1991;41:335–7.

    PubMed  CAS  Google Scholar 

  77. Asakawa H, Hayashi I, Fukui T, Tokunaga K. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Diabetes Res Clin Pract. 2003;61:175–82.

    PubMed  CAS  Google Scholar 

  78. Potet F, Bouyssou T, Escande D, Baro I. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther. 2001;299:1007–12.

    PubMed  CAS  Google Scholar 

  79. Scarpellini E, Tack J. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin Investig Drugs. 2008;17(11):1663–70.

    PubMed  CAS  Google Scholar 

  80. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120:354–60.

    PubMed  CAS  Google Scholar 

  81. De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008;20(2):99–112.

    PubMed  Google Scholar 

  82. Camilleri M, Manini M, McKinzie S, Sweetser S, Grudell A, Ryks MD, et al. Dose-related effects of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity, on gastrointestinal (GI) and colonic transit in healthy volunteers. Neurogastroenterol Motil. 2008;20 Suppl 2:6.

    Google Scholar 

  83. Smith JA, Beattie DT, Marquess D, Shaw JP, Vickery RG, Humphrey PP. The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008;378(1):125–37.

    PubMed  CAS  Google Scholar 

  84. Malagelada JR, Rees WD, Mazzotta LJ, Go VL. Gastric motor abnormalities in diabetic and postvagotomy gastroparesis: effect of metoclopramide and bethanechol. Gastroenterology. 1980;78(2):286–93.

    PubMed  CAS  Google Scholar 

  85. McCallum RW, Fink SM, Lerner E, Berkowitz DM. Effects of metoclopramide and bethanechol on delayed gastric emptying present in gastroesophageal reflux patients. Gastroenterology. 1983;84:1573–77.

    PubMed  CAS  Google Scholar 

  86. Parkman HP, Knight LC, Borwn KL, Trate DM, Maurer AH, Fisher RS. Cholinergic effects on human gastric motility. Gut. 1999;45:346–54.

    PubMed  CAS  Google Scholar 

  87. Kishibayashi N, Karasawa A. Effects of KW-5092 on antroduodenal coordination and gastric emptying in guinea pigs. J Pharm Pharmacol. 1998;50:1045–50.

    PubMed  CAS  Google Scholar 

  88. Ueki S, Seiki M, Yoneta T, Aita H, Chaki K, Hori Y, et al. Gastroprokinetic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats. J Pharmacol Exp Ther. 1003;264:152–7.

    Google Scholar 

  89. McCallum R, Zarling E, et al. Nizatidine controlled release has gastric prokinetic effects in patients with gastroesophageal reflux disease (GERD). Gastroenterology. 2004;126 Suppl 2:A-335.

    Google Scholar 

  90. Parkman HP, Miller MA, Trate DM, Urbain J-L, Knight LC, Brown KL, et al. Effect of gastric acid suppressants on human gastric motility. Gut. 1998;42:243–50.

    PubMed  CAS  Google Scholar 

  91. Seto K, Sasaki T, Katsunuma K, Kobayashi N, Tanaka K, Tack J. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil. 2008;20(9):1051–9.

    PubMed  CAS  Google Scholar 

  92. Suzuki H, Hibi T. Acotiamide (Z-338) as a possible candidate for the treatment of functinal dyspepsia. Neruogastroenterol Motil. 2010;22:585–99.

    CAS  Google Scholar 

  93. Tack J, Masclee A, Heading R, Berstad A, Piessevaux H, Popiela T, et al. A dose-ranging, placebo-controlled, pilot trial of acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil. 2009;21:272–80.

    PubMed  CAS  Google Scholar 

  94. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325:1461.

    PubMed  CAS  Google Scholar 

  95. Edmunds MC, Chen JD, Soykan I, et al. Effect of octreotide on gastric and small bowel motility in patients with gastroparesis. Aliment Pharmacol Ther. 1998;12:167.

    PubMed  CAS  Google Scholar 

  96. Rosa-E-Silva L, Troncon LES, Oliveira RB, et al. Treatment of diabetic gastroparesis with oral clonidine. Aliment Pharmacol Ther. 1995;9:179.

    PubMed  CAS  Google Scholar 

  97. Huilgol V, Evans J, Hellman RS, Soergel KH. Acute effect of clonidine on gastric emptying in patients with diabetic gastropathy and controls. Aliment Pharmacol Ther. 2002;16:945–50.

    PubMed  CAS  Google Scholar 

  98. Thumshirn M, Camilleri M, Cho M-G, et al. Modulation of gastric sensory and motor functions by nitrergic and alpha 2-adrenergic agents in humans. Gastroenterology. 1999;116:573.

    PubMed  CAS  Google Scholar 

  99. Gullikson GW, Virina MA, Loeffler R, et al. Alpha-2-adrenergic model of gastroparesis. Am J Physiol. 1991;261:G426.

    PubMed  CAS  Google Scholar 

  100. Pilichiewicz AN, Horowitz M, Russo A, Maddox AF, Jones KL, Schemann M, et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol. 2007;102(6):1276–83.

    PubMed  CAS  Google Scholar 

  101. von Arnim U, Peitz U, Vinson B, Gundermann KJ, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol. 2007;102(6):1268–75.

    Google Scholar 

  102. Braden B, Caspary W, Börner N, Vinson B, Schneider AR. Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil. 2009;21(6):632–8.

    PubMed  CAS  Google Scholar 

  103. Abouezzi ZE, Melvin WS, Ellison EC, et al. Functional and symptomatic improvement in patients with diabetic gastroparesis following pyloroplasty. Gastroenterology. 1998;114:A1374. abstract.

    Google Scholar 

  104. Miller LS, Szych GA, Kantor SB, Bromer MQ, Knight LC, Maurer AH, et al. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol. 2002;97:1653–60.

    PubMed  CAS  Google Scholar 

  105. Lacy BE, Zayat EN, Crowell MD, Schuster MM. Botulinum toxin for the treatment of gastroparesis: a preliminary report. Am J Gastroenterol. 2002;97(6):1548–52.

    PubMed  CAS  Google Scholar 

  106. Ezzeddine D, Jit R, Katz N, Gopalswamy N, Bhutani MS. Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Gastrointest Endosc. 2002;55:920–3.

    PubMed  Google Scholar 

  107. Lacy BE, Crowell MD, Schettler-Duncan VA, Mathis C, Pasricha PJ. The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus. Diabetes Care. 2004;27:2341–7.

    PubMed  CAS  Google Scholar 

  108. Bromer MQ, Friedenberg F, Miller LS, Fisher RS, Swartz K, Parkman HP. Endoscopic pyloric injection of botulinum toxin A for treatment of refractory gastroparesis. Gastrointest Endosc. 2005;61:833–9.

    PubMed  Google Scholar 

  109. Coleski R, Anderson MA, Hasler WL. Factors associated with symptom response to pyloric injection of botulinum toxin in a large series of gastroparesis patients. Dig Dis Sci. 2009;54:2634–42.

    PubMed  Google Scholar 

  110. Arts J, Holvoet L, Caenepeel P, Bisschops R, Sifrim D, Verbeke K, et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment Pharmacol Ther. 2007;26(9):1251–8.

    PubMed  CAS  Google Scholar 

  111. Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson D. Botulinum Toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol. 2008;103(2):416–23.

    PubMed  CAS  Google Scholar 

  112. Kojima M et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;401:656–60.

    Google Scholar 

  113. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes. 2001;50:1714–9.

    PubMed  CAS  Google Scholar 

  114. Camilleri M, Papathanasopoulos A, Odunsi ST. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol. 2009;6:343–52.

    PubMed  CAS  Google Scholar 

  115. Tack J et al. Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut. 2006;55:327–33.

    PubMed  CAS  Google Scholar 

  116. Asakawa A et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology. 2001;120:337–45.

    PubMed  CAS  Google Scholar 

  117. Tack J, Depoortere I, Bisschops R, Verbeke K, Janssens J, Peeters T. Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther. 2005;22:847–53.

    PubMed  CAS  Google Scholar 

  118. Murray CD, Martin NM, Patterson M, Taylor S, Ghatei MA, Kamm MA, et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double-blind, placebo-controlled, cross-over study. Gut. 2005;54:1693–8.

    PubMed  CAS  Google Scholar 

  119. Ejskjaer N, Vestergaaard ET, Hellstrom PM, Gormsen LC, Madsbad S, Madsen JL, et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther. 2009;29:1179–87.

    PubMed  CAS  Google Scholar 

  120. Ejskjaer N, Dimcevski G, Wo J, Hellstrom PM, Gormsen LC, Sarosiek I, et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol Motil. 2010;22(10):1069–e281.

    PubMed  CAS  Google Scholar 

  121. Lasseter KC, Shaughnessy L, Cummings D, et al. Ghrelin agonist (TZP-101): safety, ­pharmacokinetic and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol. 2008;48:193–201.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Gastroenterology, Department of Medicine, Temple University Hospital, Parkinson Pavilion, 8th floor, 3401 North Broad Street, Philadelphia, PA, 19140, USA

    Henry P. Parkman MD

Authors
  1. Henry P. Parkman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Henry P. Parkman MD .

Editor information

Editors and Affiliations

  1. School of Medicine, Department of Medicine, Temple University, N. Broad St. 3401, Philadelphia, 19140, Pennsylvania, USA

    Henry P. Parkman

  2. Paul L Foster School of Medicine, Department of Internal Medicine, Texas Tech University Health Sciences Ce, Alberta Avenue 4800, El Paso, 77905, Texas, USA

    Richard W. McCallum

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Parkman, H.P. (2012). Prokinetic Agents for Gastroparesis. In: Parkman, H., McCallum, R. (eds) Gastroparesis. Clinical Gastroenterology. Humana Press. https://doi.org/10.1007/978-1-60761-552-1_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-552-1_22

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-551-4

  • Online ISBN: 978-1-60761-552-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation